First human test of new ALS drug begins
NCT ID NCT06714396
Summary
This was an early, small study to see how safe a single dose of a new drug called QRL-101 is for people with ALS and to measure how the body absorbs and processes it. Twelve participants with ALS received either the drug or a placebo. The main goal was to gather initial safety data and understand how the drug behaves in the body, not to test if it improves ALS symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands, 9728 NZ, Netherlands
Conditions
Explore the condition pages connected to this study.